Scancell receives FDA Fast Track Designation for iSCIB1+ in advanced melanoma and provides data update from its SCOPE Phase 2 study

About this update from Scancell Holdings Plc

Potent and durable efficacy with iSCIB1+ of 77% progression free survival (PFS) at 20 months, in combination with ipilimumab and nivolumab, demonstrated in the Phase 2 SCOPE trial; more PFS and additional early overall survival (OS) data expected in H1 2027 Initiation of the registrational Phase 3 trial with iSCIB1+ in advanced melanoma anticipated in H2 2026 OXFORD, United Kingdom, April 28, 2026 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of active immunotherapies to treat cancer, announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its lead ImmunoBody® iSCIB1+ for the treatment of advanced melanoma. Dr Phil L'Huillier, CEO of Scancell, said: "This designation is a major achievement for Scancell and important recognition not only of the potential of iSCIB1+, but also of the significant need for new and improved treatment options for patients with advanced melanoma. We are very pleased with how the Phase 2 SCOPE data is maturing and are advancing plans for a global registrational Phase 3 trial, which we expect to initiate in the second half of 2026." Progression free survival (PFS) has matured positively, reaching 77% at 20 months in the target population1. This widens the lead of iSCIB1+ over PFS reported with ipilimumab plus nivolumab alone of 43% at 20 months, now representing a 30+ percentage point improvement over standard of care (SoC).2 The Fast Track Designation is granted for investigational therapies that show advantage over available treatments, such as superior effectiveness, and provides the process to expedite review of drugs for serious conditions, with the aim of getting effective therapies to patients faster.  The designation enables frequent engagement to ensure alignment on development plans, enhance development predictability and support a more efficient path through clinical development. Moreover, Fast Track Designation brings eligibility for Accelerated Approval, Priority Review and Rolling Review. Additional PFS data and early OS data from the Phase 2 SCOPE study are expected in H1 2027. This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR). About the SCOPE Phase 2 study The SCOPE study (NCT04079166) is a Phase 2, Multicentre, Open-Label, Study in Advanced Unresectable Melanoma. Patie...

View stock analysis, news, and events for Scancell Holdings Plc